Trials / Completed
CompletedNCT00435669
A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)
Mass Balance, Pharmacokinetics and Metabolism of [14C]BMS-582664 Prodrug of BMS-540215, in Subjects With Advanced or Metastatic Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to determine the mass balance, pharmacokinetics, metabolism, and routes and extent of elimination of BMS-582664
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brivanib | Oral Solution, Oral, 800 mg, X1 on Day 1, 10 D for ADME |
| DRUG | Brivanib | Tablet, Oral, Brivanib 800 mg, QD, until progression |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2007-02-15
- Last updated
- 2009-01-22
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00435669. Inclusion in this directory is not an endorsement.